Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERACT: Luvadaxistat for negative symptoms of schizophrenia
NCT03382639Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of luvadaxistat in schizophrenia (4 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Positive and Negative Syndrome Scale Negative Symptom Factor Score at 12 weeks. Started Jan 2018; status: completed.
02
Drugs
luvadaxistat
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03382639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382639.